Dr. Justin David Brown, D.D.S. Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 5 Logan St, Peru, IN 46970 Phone: 765-473-9336 Fax: 765-473-9346 |
Dr. Sara Jayne Musselman, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 65 E 2nd St, Peru, IN 46970 Phone: 765-473-5959 |
Melody Miller Richardson, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 63 West 6th St, Peru, IN 46970 Phone: 765-473-4109 |
Dr. Skye Bower, DDS Dentist Medicare: Not Enrolled in Medicare Practice Location: 33 W 7th St, Peru, IN 46970 Phone: 765-473-5300 |
Dr. John Robert Davidson, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 27 N Park Ave, Peru, IN 46970 Phone: 765-475-4422 |
Dr. David Phillip Zandi, DDS Dentist Medicare: Medicare Enrolled Practice Location: 33 W 7th St, Peru, IN 46970 Phone: 765-473-5300 Fax: 765-473-7845 |
Dr. Thomas J Guthrie, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 5 West Logan Street, Peru, IN 46970 Phone: 765-473-9336 Fax: 765-473-9346 |
Dr. Byron Leon Cohee, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 65 E 2nd St, Peru, IN 46970 Phone: 765-473-5959 |
News Archive
Overexpression or hyperactivation of ErbB cell-surface receptors drives the growth of many breast cancers. Drugs, like Herceptin, that block the receptors' signals halt tumor progression in some patients.
Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, announced today that the Duchenne Parent Project, based in the Netherlands, has awarded AMT a grant of EUR 145,000 to support the development of AMT-080, AMT's gene therapy for Duchenne Muscular Dystrophy.
Disruption of the normal interaction between the genes PRODH and COMT contributes directly to major symptoms of schizophrenia by upsetting the balance of the brain chemicals glutamate and dopamine, according to a group of investigators that includes a scientist now at St. Jude Children's Research Hospital.
NeuroVive announces publication of the results of a Phase I clinical trial of lead product CicloMulsion in the scientific journal Clinical Drug Investigation. The paper highlights that the intravenous cyclosporine formulation CicloMulsion demonstrates bioequivalence and improved tolerability when compared with Sandimmune Injection.
› Verified 6 days ago